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1. Introduction 
Epidermal growth factor (EGF) receptor (EGFR), also known as HER1 or ErbB1, is the 
prototypal member of the superfamily of receptors with intrinsic tyrosine kinase activity 
and is widely expressed in many cell types including epithelial and mesenchymal lineages 
[1, 2]. The other three members of the ErbB receptor family include Her2/ErbB2/neu [3, 4], 
Her3/ErbB3 [5] and Her4/ErbB4 [6] (Fig. 1A). EGFR is a 170 kDa membrane glycoprotein 
composed of three domains. The heavily glycosylated 622-amino acid extracellular domain 
containing two cysteine rich regions is responsible for ligand binding. The transmembrane 
domain is a single 23-amino acid α-helical transmembrane peptide. The 542-residue 
intracellular cytoplasmic domain contains a 250-amino acid conserved protein tyrosine 
kinase core followed by a 229-amino acid C-terminal tail with regulatory tyrosine residues 
(Fig. 1B) [7]. Eleven ligands have been identified for ErbB receptors. These ligands can be 
classified into three groups based on their ability to bind to different ErbB receptors. The 
first group of ligands includes EGF, transforming growth factor-α, amphiregulin and epgen, 
which specifically binds to EGFR. The second group of ligands includes betacellulin, 
heparin-binding EGF and epiregulin, which binds to both EGFR and ErbB4. The third group 
of ligands includes neuregulin/heregulin, which binds to ErbB3 and ErbB4 [8, 9] (Fig. 1A). 
The EGFR family of receptor tyrosine kinases lies at the head of a complex signal 
transduction cascade that modulates cell proliferation, survival, adhesion, migration and 
differentiation [1, 2, 10]. While growth factor-induced EGFR signalling is essential for many 
normal morphogenic processes and is involved in numerous additional cellular responses, 
the aberrant activity of the members of this receptor family has been shown to play a key 
role in the development and growth of tumour cells [10-12]. The ErbB receptors were first 
implicated in cancer when the avian erythroblastosis tumor virus was found to encode an 
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aberrant form of EGFR. Now, EGFR has been implicated in many cancers including 
squamous cell head and neck cancer, colorectal cancer, non-small cell lung cancer, gastric 
cancer, pancreatic cancer, breast cancer, ovarian cancer, renal cancer, glimas prostatic cancer 
and cervical cancer [13]. The dysregulation of ErbB receptor signalling in cancer can occur 
by various mechanisms, including overexpression due to gene amplification, autocrine 
ligand production, heterodimerization, deficiency in endocytosis, and gene mutations that 
increase receptor transcription, translation, protein stability and kinase activity[14, 15].  
 
Figure 1. ErbB receptor family. (A) ErbB receptors and their ligands. ErbB family receptors are 
composed of four members: EGFR/ErbB1/Her1, ErbB2/Her2/neu, ErbB3/Her3 and ErbB4/Her4. Eleven 
ligands are identified for ErbB family receptors. (B) Linear structure of EGFR.  
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The binding of EGF at the cell surface induces dimerization of EGFR, which results in the 
activation of EGFR tyrosine kinase and receptor trans-autophosphorylation [16, 17]. EGFR 
activation stimulates various signaling pathways, leading to cell mitogenesis and survival [9, 
10]. EGFR is overexpressed or hyper activated in many epithelial tumors and plays important 
roles in cancer development and progression [12]. The activated receptors are rapidly 
internalized into endosomes and eventually degraded in lysosomes [18]. Initially, the 
endocytosis of ligand-activated receptors was considered a mechanism to attenuate signaling. 
Recently, more evidence suggests that the internalized receptors may maintain their ability to 
generate cell signaling in endosomes [19-23]. Thus, the alteration of EGFR endocytosis may 
result in abnormal cell signaling, leading to cancer. On the other hand, EGFR endocytosis is 
firmly regulated by signal recognition and various signaling proteins at every step. 
2. EGFR-mediated cell signaling 
EGFR plays important roles in initiating cell signaling to produce specific effects on cell 
growth and development [9, 10]. EGFR is activated through the homodimerization or 
heterodimerization with other ErbBs such as ErbB2 and ErbB3 in response to ligand 
stimulation (Fig. 2)[2]. The dimerization of EGFR at the plasma membrane induces the 
activation of the EGFR tyrosine kinase and trans-autophosphorylation. The sites of tyrosine 
phosphorylation in the activated EGFR form signaling complexes with many signaling 
proteins, including Grb2, Shc, phospholipase C-γ1 (PLC-γ1), the p85α subunit of PI3K (p85), 
p120 rasGAP, Src, Stats, and Cbl [2, 24-26] [2]. The formation of the receptor-signaling protein 
complexes then initiates the activation of various signaling pathways (Fig. 3A)[9-11, 27-29].  
 
Figure 2. Dimerization of EGFR and the association with signaling proteins. EGFR is homodimerized or 
heterodimerized with other ErbB proteins in response to ligand.  
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Figure 3. Signaling pathways activated by EGFR. (A) Binding of EGF to EGFR at the plasma membrane 
initiate the activation of various signaling pathways. The well-defined pathways include Ras-Erk 
pathway, PI3K-Akt pathway, PLC-γ1 pathway, Stat pathway and Src pathway. (B)The signaling 
cascade of Ras-Erk pathway. (C) The signaling cascade of PLC-γ1 pathway. (D) The signaling cascade of 
PI3K-Akt pathway. 
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The activated EGFR interacts with Shc and Grb2 through multiple phosphorylated tyrosine 
(pY) residues localized at the C-terminus, which results in the recruitment of Sos to the 
plasma membrane to activate Ras. Activated Ras mediates Raf activation, which then 
phosphorylates and activates MEK. Activated MEK then phosphorylates and activates ERK. 
Activated ERK phosphorylates Rsk, which in turn translocates into the nucleus to activate 
transcription factors such as c-fos and SRF. Activated ERK may also translocate into the 
nucleus to activate transcription factors such as Elk1 and c-fos, which is critical in 
controlling cell mitogenesis (Fig. 3B) [2, 24, 30-34]. 
Activated EGFR also interacts with PLC-γ1 with multiple pY residues at the C-terminal 
regulatory domain, which results in the phosphorylation of PLC-γ1 and an increase in its 
enzymatic activity [35-37]. Active PLC-γ1 hydrolyzes phosphatidylinositol 4, 5-
bisphosphate (PtdIns(4,5)P2) to form the second messengers inositol 1, 4, 5-triphosphate 
(InsP3) and diacylglycerol (DAG). InsP3 and DAG mobilize intracellular calcium and activate 
protein kinase C (PKC), respectively. Recent studies have shown that PLC-γ1 is involved in 
broad cell signaling. Interestingly, most recently identified interactions between PLC-γ1 and 
its binding proteins are mediated by its SH3 domain. EGF stimulates the interaction 
between PLC-γ1 and PLD2, which is mediated by the PLC-γ1 SH3 domain [38]. PLC-γ1 
binds directly to Akt in response to EGF through its SH3 domain [39]. The PLC-γ1 SH3 
domain acts as a guanine nucleotide exchange factor (GEF) for PIKE [40], dynamin [41] and 
Rac1 [42]. The activated PLC-γ1 regulates cell mitogenesis and migration (Fig. 3C)[39, 42-
44].  
Activated EGFR also activates PI3K either through its direct interaction with the p85α 
subunit or through the activated Ras [45, 46]. Activated PI3K then catalyzes the production 
of the second messenger phosphatidylinositol-3,4,5-trisphosphate (PIP3) by phosphorylating 
phosphatidylinositol-4,5-bisphosphate (PIP2). A direct antagonist of PI3K is the phosphatase 
and tensin homologue deleted on chromosome 10 (PTEN). PTEN dephosphorylates PIP3 
into PIP2 to reverse the activity of PI3K and therefore function as an important negative 
controlling element of incoming signals. PIP3 transduces activating signals by binding to 
pleckstrin homology (PH) domains of proteins to recruit them to the cell membrane. One 
centrally important downstream mediator of the PI3K signalling cascade is the serine 
threonine (Thr) kinase Akt. Akt is recruited to the plasma membrane by its SH3 domain 
interaction with PIP3, which exposes Akt Thr 308 for phosphorylation by 3-
phosphoinositide-dependent kinase 1 (PDK-1), which is already located at the membrane. 
The rapamycin complex 2 (mTORC2) phosphorylates Ser 473 in the C-terminus, which leads 
to full Akt activation. Activated Akt then mediates signals promoting cellular growth and 
survival and suppresses pro-apoptotic signals. Akt phosphorylates several intracellular 
proteins, including forkhead box O transcription factors (FoxO), the BCL2-associated 
agonist of cell death (BAD), and the glycogen synthase kinase 3 (GSK3), to promote cell 
cycle entry and cell survival. The proteins TSC1 (Hamartin) and TSC2 (Tuberin) form a 
complex that inhibits the activity of the small G-protein ras homologue enriched in the brain 
(Rheb), which is necessary for mTORC1 activation. The Akt-mediated phosphorylation of 
TSC2 releases Rheb from its inhibited state. Rheb then accumulates in a GTP-bound state 
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and can directly activate mTORC1, which phosphorylates the p70S6 kinase (S6K1) and the 
eukaryotic translation initiation factor 4E binding protein 1 (4EBP1), leading to increased 
protein translation (Fig. 3D), which protects the cell from undergoing apoptosis [45, 47, 48].  
Activated EGFR also activate Stats directly by binding to and phosphorylating Stats, or 
indirectly by activating c-Src. Activation can occur via cytokine signaling (IL-6), growth 
factor receptor signaling (EGFR), or non-receptor tyrosine kinase signaling (Src). JAK is not 
required when Stats bind directly to EGFR for activation, but JAK provides maximal 
activation of Stats phosphorylated by EGFR-activated Src. Grb2 and SOCS can inhibit Stat-
mediated EGFR signaling respectively, by either binding to the STAT activation site on 
EGFR or by binding to JAK to suppress Src activation of Stats. Once activated, Stats 
dimerize and translocate to the nucleus where they activate the transcription of genes 
involved in proliferation, differentiation, and survival [49].  
Importantly, Src kinases, which have been reported to be activated in many cancers with 
high EGFR levels, have been shown to potentiate EGFR signaling [50-52]. The c-Src 
potentiation of EGFR has been demonstrated to be associated with the c-Src-dependent 
phosphorylation of EGFR and the complex formation between c-Src and EGFR [50, 51]. In 
addition to focal adhesion kinase (FAK), which is involved in the regulation of adhesion and 
migration, PI3K and Stat3 are also substrates for c-Src [53]. Although the Src kinase has been 
linked with the development and progression of cancer for many years, we still do not 
completely understand its role in cancer [54]. Src is a member of a ten-gene family (FYN, 
YES, BLK,FRK, FGR, HCK, LCK LYN, and SRMS) of non-RTKs that play a fundamental role 
in the regulation of cell proliferation, migration, adhesion, and tumor angiogenesis [55, 56]. 
Src signaling is cross-connected with many signaling pathways, such as the PI3K and Stat 
pathway [55, 56]. Even though tyrosine kinase activity of Src is independent of RTK 
signaling, it may interact with RTKs such as EGFR. As such, Src-EGFR interaction may 
enhance EGFR signaling, and on the other hand it may be involved in resistance to EGFR-
targeted therapy [54, 57]. 
3. EGFR-mediated endocytosis 
3.1. Clathrin-dependent and clathrin-independent endocytic pathways 
The concept of receptor-mediated endocytosis was formulated in 1974 to explain how the 
sequential cell surface binding, internalization, and intracellular degradation of plasma low 
density lipoprotein (LDL) regulates cellular cholesterol metabolism [58]. Receptor-mediated 
endocytosis is a multiple step event [58]. In general, receptor-mediated endocytosis consists 
of two stages: internalization and intracellular trafficking. Endocytic pathways are generally 
classified as either clathrin-dependent or clathrin-independent. Much work has focused on 
clathrin-mediated endocytosis (CME). In this process, cargo proteins are recruited into 
developing clathrin-coated pits (CCPs), and subsequently form clathrin-coated vesicles 
(CCVs) [59]. Several proteins or protein complexes, including clathrin, adaptin AP-2, 
dynamin and Eps15, participate in the CME of all receptors. Adaptin AP-2 is a cytoplasmic 
protein complex that interacts with the cytoplasmic tails of various receptors. These 
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interactions are thought to account for the ability of cells to selectively direct receptors to 
CCVs. Clathrin is ideally designed to form a scaffold which, when attached to the 
membrane, causes the membrane to deform into a budding vesicle. Clathrin presumably 
binds to the membrane by interacting with membrane-bound AP-2. Dynamin has been 
identified as a major player in the endocytic pathway and is essential for the scission of 
coated vesicles. Eps15 is an essential component of the early endocytic pathway [59-61].  
Although CME is certainly an extremely important endocytic mechanism, accounting for a 
large proportion of endocytic events, an ever expanding array of cargos has been shown to 
undergo non-clathrin-mediated endocytosis (NCE) [62]. Many NCE pathways have been 
reported, including caveolar-type endocytosis, CLIC/GEEC-type endocytosis, the putative 
flotillin-associated endocytic structures, phagocytosis, macropinocytosis, dorsal ruffles (or 
waves), and entosis [62, 63]. Caveolar-type endocytosis is the best studied NCE.  
3.2. Endocytic and sorting signals 
The targeting of transmembrane proteins to different compartments of the endocytic 
pathways is largely dependent upon sorting signals contained within the cytoplasmic 
domains of the proteins [64-66]. Most of these sorting signals are short, linear sequences of 
amino acid residues. These signals can be classified to two groups. One group of signals is 
referred to as tyrosine-based sorting signals and the other group of signals is known as 
dileucine-based signals. All of these signals are recognized by components of protein coats 
peripherally associated with the cytosolic face of membranes [66]. 
Tyrosine-based signals constitute a family of degenerate motifs minimally defined by the 
presence of a critical tyrosine residue [66]. Most tyrosine-based signals conform to the 
consensus motifs YXXΦ (Y is tyrosine, X is any amino acid and Φ is an amino acid with a 
bulky hydrophobic side chain) [67] or NPXY (N is asparagine and P is proline) [68-71]. It 
was shown by several groups that the substitution of tyrosine residues in the cytosolic 
domains of various endocytic receptors devoid of NPXY motifs impaired internalization [72-
77]. NPXY signals have been shown to mediate only the rapid internalization of a subset of 
type I integral membrane proteins, and not mediate other intracellular sorting events. The 
interaction between NPXY motif and endocytic protein is less understood. However, several 
proteins, including clathrin, AP-2, and Dab2, have been proposed to function as recognition 
proteins for NPXY signals. There are several NPXY motifs located in the EGFR C-terminus 
[78]. Systematic mutational analyses led to the identification of another tyrosine-based 
motif, YXXΦ, as the major determinant of endocytosis of the mannose 6-phosphate as well 
as many other transmembrane proteins [67, 78, 79]. In mammalian cells, virtually all YXXΦ 
signals mediate rapid internalization from the cell surface. Some YXXΦ signals can 
additionally mediate lysosomal targeting [64-66]. Recent evidence suggests that the µ2 
subunit of AP2 directly interacts with YXXΦ to mediate rapid internalization [80-83].  
Di-leucine-based sorting signals have been implicated in various sorting process [78]. Two 
classes of di-leucine-based sorting motifs have been distinguished. [DE]XXXL[LI] signals 
play critical roles in the sorting of many type I, type II and multispanning transmembrane 
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proteins. The [DE]XXXL[LI] signals in mammalian proteins mediate rapid internalization 
and target the proteins to endosomal-lysosomal compartments, suggesting that they can be 
recognized both at the plasma membrane and at intracellular locations. [DE]XXXL[LI] 
signals are recognized by the adaptor protein (AP) complexes. DXXLL signals are present in 
several transmembrane receptors and other proteins that cycle between the TGN and 
endosomes. DXXLL signals are recognized by another family of adaptors known as GGAs. 
Ubiquitination of cytosolic lysine residues constitutes another important signal for sorting 
transmembrane receptors at various stages of the endosomal-lysosomal system. Ubiquitin is 
a globular protein consisting of 76 amino acids that is able to covalently conjugate to other 
proteins [84]. Ubiquitin is covalently conjugated to proteins by forming a bond between the 
carboxy-terminal glycine of ubiquitin and the ε-NH2 group of a lysine residue in the 
substrate protein. Alternatively, ubiquitin can be conjugated to the α-NH2 group of the N-
terminal amino acid of the substrate [85, 86]. Conjugated ubiquitin is recognized by UIM, 
UBA, or UBC domains present within many components of the internalization and 
lysosomal targeting machinery. It has been shown that EGFR is ubiquitinated in response to 
EGF, which plays an important role in EGFR degradation in lysosomes. The presence of 
these various type of sorting signals within the transmembrane receptors and their 
interaction with the signal recognition proteins ensures the dynamic but accurate 
distribution of transmembrane proteins to different compartments along the endocytic 
pathways. 
3.3. Endocytosis of EGFR 
The first comprehensive study of EGF endocytosis, in which many of the key concepts of 
internalization and lysosomal degradation of EGF have been established, was published by 
Carpenter and Cohen [87]. The binding of EGF results in the clustering and internalization 
of EGFR. The accumulation of EGF and EGFR can be detected in the early endosome after 1-
5 min of incubation with EGF at 37oC. EGF and EGFR accumulate in late endosomes after 
10-20 min at 37oC. A substantial number of EGFR can be detected in organelles with typical 
biochemical and morphological features of mature lysosomes only after 40-60 min of 
continuous internalization at 37oC [16, 88]. Intracellular trafficking of receptors involves a 
series of membrane budding and fusion events [89]. Endosome fusion is regulated by 
specific cytosolic and membrane-associated protein factors, including a group of Ras-like 
small guanosine triphosphatases (GTPases) called Rabs [90-92]. Four classes of endocytic 
organelles are typically distinguished based largely on their relative kinetics of labeling by 
endocytic tracers: early endosomes (EEs), late endosomes (LEs), recycling vesicles (RVs), 
and lysosomes [65]. The precise relationship among these structures has yet to be 
determined, and in fact may never be known because of the great plasticity and dynamics of 
the system. 
The internalization of constitutively internalized receptors is largely mediated by sorting 
signals such as YXXΦ and NPXY. However, for the receptors that are internalized in 
response to ligand binding, there is likely some means of switching their sorting signals on 
and off [93]. Given that ligand binding is essential for the rapid internalization of EGFR, the 
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events induced by the ligand binding likely contribute to the regulation of ligand-induced 
EGFR internalization. These events include receptor dimerization, activation of intrinsic 
tyrosine kinase activity, autophosphorylation and association with various binding proteins.  
The initial results are very controversial regarding the role of EGFR kinase activity in EGFR 
internalization. Data from some research groups suggest that kinase-dead EGFR is deficient 
in EGF-induced internalization [94, 95]; however, data from other research groups suggest 
that kinase-dead EGFR is internalized normally like wild type EGFR, but is quickly recycled 
back to the plasma membrane [96, 97]. Since the mid 1990s, most studies suggest that EGFR 
kinase activity is required for EGF-induced EGFR internalization. It was reported that EGFR 
kinase activation is required for the recruitment of EGFR into coated pits [98]. The EGFR 
activation of c-Src tyrosine kinase has been implicated in the regulation of the clathrin-
dependent endocytosis of EGFR through the ability to phosphorylate clathrin heavy chain 
[99]. The EGFR activation of Eps15 has been shown to be required for the internalization of 
EGFR [100]. The inhibition of EGFR kinase activity by AG1478 and PD158780 was shown to 
block EGFR internalization [101, 102].  
While most studies indicate that EGFR kinase activity is essential for EGF-induced EGFR 
internalization [94, 95, 98-102], it was shown recently that EGFR kinase activity is not 
required for EGF-induced EGFR internalization [103-107]. Inhibition of EGFR kinase 
activation by the specific inhibitor AG1478 and PD158780 in BT20, MDCK, Cos7 and Hela 
cells did not block EGFR internalization. When transiently expressed in 293T cells or stably 
expressed in CHO cells, a kinase-dead EGFR (EGFR K721A), was internalized following 
EGF stimulation in a similar pattern to wild type EGFR, which indicates that EGFR kinase 
activation is not required for EGFR internalization [103-107].  
If kinase activity is not necessary for EGF-induced EGFR endocytosis, an EGF-induced event 
before or independent of EGF-induced EGFR kinase activation must be responsible for 
mediating EGF-induced EGFR endocytosis. The only significant event induced by EGF 
before the activation of EGFR kinase is the dimerization of EGFR. It is well established that 
receptor dimerization is critical for EGFR kinase activation [108]. In fact, it is generally 
believed that the only function of receptor dimerization is to allow the activation of EGFR 
kinase and the trans-autophosphoylation of the two receptors. However, it was shown 
recently that EGFR dimerization is necessary and sufficient to stimulate EGFR 
internalization, independent of EGFR kinase activation [105]. EGF-induced EGFR 
dimerization in the absence of kinase activation is sufficient to stimulate EGFR 
internalization. Non-ligand-induced dimerization of EGFR without kinase activation is 
sufficient to stimulate EGFR internalization. Moreover, the inhibition of EGF-induced EGFR 
dimerization by deleting the receptor dimerization loop abolishes EGF-induced EGFR 
internalization [105]. It has also been reported that the crosslinking of two EGFR with 
antibody stimulates the endocytosis of EGFR without activating EGFR kinase [109]. How 
dimerization may mediate EGFR endocytosis independent of its role in EGFR kinase 
activation is not known. Several possibilities have been suggested. It is possible that EGF-
induced EGFR dimerization causes necessary conformational changes of the receptor to 
expose the cryptic internalization codes. Alternatively, the internalization regulating 
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proteins essential for EGFR internalization may have a dimeric nature and can only bind to 
dimerized EGFR [105].  
Many studies have also focused on the role of EGFR C-terminus in EGFR internalization 
(Fig. 4). The EGFR mutants truncated from the C-terminus to residue 991 [110] or to residue 
973 [111] are internalized inefficiently and the mutant truncated at residue 958 is not 
internalized [110]. Simultaneous point mutation of the five-tyrosine residues (Y992, Y1068, Y 
1086, Y1148 and Y1173) to phenylalanines significantly reduces EGFR internalization [112]. 
EGFR is co-immunoprecipitated with adaptin AP-2 [88]. The binding between EGFR and 
AP-2 is mediated by EGFR amino acid residues 970-991, especially Y974 [113, 114]. This 
interaction accelerates EGFR internalization when EGFR is expressed at high levels, but is 
not required for EGFR internalization when EGFR is expressed at low levels [83, 113, 114]. A 
15-amino acid domain (residues 943-957) was found to be essential for binding sorting 
nexin-1 (SNX1) which is involved in targeting EGFR to lysosome [115], but not EGFR 
internalization. It was shown that the EGFR C-terminal sequences from 992 to 1044 are 
essential for mediating EGF-induced EGFR internalization with or without the inhibition of 
EGFR kinase activation [105]. It was further shown that EGFR residues 1005-1017, especially 
the di-leucine 1010LL1011 is required for EGF induced rapid internalization of full length EGFR 
and the role of 1010LL1011 in EGFR internalization is independent of EGFR kinase activation 
[106]. The identification of 1010LL1011 as essential for EGFR internalization is very interesting. 
EGFR di-leucine motif 1010LL1011 proceeded with TSRTP, which is different from the two 
classes of di-leucine-based sorting signals described above. Two di-leucine motifs including 
679LL680 and 1010LL1011 have been implicated in EGFR sorting. It was reported that 679LL680 is 
required for the efficient transport of EGFR to lysosomes and for the retention of EGFR in 
endosomes [116, 117]. It was also shown that 1010LL1011 is critical in the tyrosine 
phosphorylation of β2 subunit of clathrin adaptor complex AP-2 and is required for EGFR 
degradation [118]. The only data suggesting a possible role of 1010LL1011 in EGFR endocytosis 
is that it regulates the slow endocytosis of a mutant EGFR truncated at amino acid 1022 
[119]. However, other data from the same group showed that 1010LL1011 is not involved in the 
endocytosis of full length EGFR [118, 119].  
The role of various EGFR binding proteins in EGFR endocytosis has also been extensively 
studied. Some proteins that bind to pY sites of EGFR have also been implicated in EGFR 
endocytosis. These proteins including Grb2, Eps15, PLD, Cbl, Rin1, and Src [41, 99, 100, 119-
123]. Grb2 regulates EGFR endocytosis, possibly through its SH3 domain interaction with 
dynamin [120]. Knocking-down Grb2 with siRNA also blocks EGFR endocytosis [119, 124]. 
EGF receptor endocytosis is dependent upon PLD and the PLD1 regulators, protein kinase 
C alpha and RalA [125]. Tyrosine phosphorylation of Eps15 is necessary for the 
internalization of EGFR [100]. Eps15 functions as a scaffolding adaptor protein and is 
involved in both secretion and endocytosis. Eps15 has been shown to bind to AP-1 and AP-2 
complexes, to inositol lipids, and to several other proteins involved in the regulation of 
intracellular trafficking [126]. Phosphorylation of clathrin heavy chain by Src facilitates 
EGFR endocytosis [99]. Rin1 binds to EGFR and regulates EGFR endocytosis through its 
SH2 domain [123]. Although it is generally agreed that Cbl acts to negatively regulate EGFR 
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activity by promoting the intracellular trafficking and degradation of EGFR, it is still 
disputed whether Cbl binding or Cbl-mediated ubiquitination is altogether required for 
ligand-induced EGFR endocytosis [122, 127]. Some recent data indicate that Cbl-mediated 
ubiquitin of EGFR is not required for EGFR endocytosis [127, 128]. While PI3K is required 
for β-PDGFR endocytosis and down-regulation [129-131], PI3K activity is not required for 
EGFR endocytosis [132].  
 
Figure 4. Internalization and sorting signals within EGFR intracellular domain. 
Strong evidence suggests that CME is the major pathway of EGFR endocytosis. EGF and 
EGFR are found concentrated in CCP and CCV. EGFR endocytosed with a rate similar to 
those of other receptors that are internalized by CME, such as LDL and transferrin (Tfn). 
Knockdown of clathrin heavy chain or dynamin by RNA interference (RNAi) inhibits EGFR 
endocytosis [18]. Although CME is certainly an extremely important endocytic mechanism, 
accounting for a large proportion of endocytic events, an ever expanding array of cargos has 
been show to undergo endocytosis in clathrin-independent manner [62, 133]. Clathrin-
independent endocytosis itself has been further dissected into seemingly distinct pathways, 
based on the reliance of these pathways on certain proteins and lipids, their differential drug 
sensitivities and their abilities to internalize particular cargos [134]. Many NCE pathways 
have been reported including caveolar-type endocytosis, CLIC/GEEC-type endocytosis, the 
putative flotillin-associated endocytic structures, phagocytosis, macropinocytosis, dorsal 
ruffles (or waves), and entosis [62, 63]. New evidence suggests that EGF-induced EGFR 
endocytosis may also be mediated by NCE. NCE of EGFR via dorsal waves was observed in 
several types of cells [135]. This pathway required the activity of the EGFR kinase, PI3K and 
dynamin [135]. The NCE of EGFR involving cholesterol-rich lipid rafts and/or caveolar has 
also been reported [136]. This cholesterol-dependent endocytosis was observed under 
conditions of high EGFR occupancy by EGF in Hela cells. All of the reported NCE pathways 
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are significantly slower than CME, although they are faster than constitutive receptor 
endocytosis [18].  
4. Regulation of EGFR signalling by endocytosis 
Endocytosis is essential for cells to perceive extracellular signals and transduce them in a 
temporally and spatially controlled fashion, directly influencing not only the duration and 
intensity of the signaling output, but also their correct location. It is well established that the 
endocytosis of EGFR from the plasma membrane to lysosomes results in the degradation of 
the receptor, which can attenuate receptor signaling and may even be conceived of as a 
tumor suppressor pathway [19]. On the other hand, accumulated evidence suggests that the 
internalized EGF-EGFR complex may maintain its ability to generate cell signaling from 
endosomes [19-23].  
4.1. Downregulation of EGFR by endocytosis 
Endocytosis has been recognized as the most significant pathway to downregulate EGFR by 
removing the receptor from the cell surface for degradation in lysosomes [137]. This 
downregulation of EGFR is a complicated and tightly regulated process. During this process 
the EGFR-containing internalized vesicles mature into multivesicular bodies (MVBs), which 
then fuse with lysosomes to allow degradation of their content. This was first shown by 
Cohen and his colleagues, who observed that ferritin-conjugated EGF was rapidly 
internalized upon binding to EGFR and trafficked to MVBs within 15 minutes exposure of 
cells to ligand [87, 138]. The impaired endocytic downregulation of signaling receptors is 
frequently associated with cancer, since it can lead to increased and uncontrolled receptor 
signaling [139].  
The role of endocytosis in the downregulation of EGFR signalling is best illustrated by the 
findings that the inhibition of EGFR endocytosis frequently leads to cancer. The best 
characterized EGFR mutant with impaired endocytosis is EGFRvIII. EGFRvIII has been 
implicated in many types of tumors [140-145]. EGFRvIII is a mutant EGFR with the deletion 
of amino acid residues 6–273 in the extracellular domain of EGFR. This results a truncated 
145 kDa receptor with a non-functional ligand binding pocket and no dimerization arm. In 
spite of not binding any ligands, the receptor is constitutively active [146], and is able to 
activate Ras-Erk1/2 and PI 3-kinase-Akt pathways [142, 147]. In concordance with this, 
EGFRvIII was shown to transform fibroblasts and to enhance the proliferation and/or 
tumorigenicity of cells both in vivo and in vitro [142, 148-152]. The constitutive activity may 
be important for tumorigenicity, but impaired downregulation certainly enhances the effect. 
Two recent reports show that EGFRvIII is not degraded in cells with endogenous levels of 
Cbl, instead, internalized EGFRvIII is recycled back to the plasma membrane [153].  
It is generally accepted that ErbB2 avoids efficient endocytic downregulation [154-158], 
which contributes to its important role in the development of various cancers [2, 10]. As 
ErbB2 and the EGFR-ErbB2 heterodimers are impaired in EGF-induced endocytosis [158], 
EGFR-mediated cell signaling are significantly sustained in the cells with overexpressed 
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ErbB2 due to the formation of EGFR-ErbB2 heterodimers. EGFR signaling can also be 
sustained if the molecular machinery normally involved in receptor downregulation does 
not function optimally. Indeed, several mutations of such proteins have been found in 
tumors, including Cbl, TSG101 (an ESCRT-I subunit), and VPS25 (an ESCRT-II subunit) 
(recently reviewed in [159]. In conclusion, endocytic impairment may be a returning theme 
of oncogenic EGFR mutants.  
The role of endocytosis in the downregulation of EGFR signalling is also frequently and 
successfully explored as a therapy for cancer. Since the lack of endocytic downregulation is 
an emerging theme in ErbB cancer biology, it is evident that the stimulation of ErbB 
endocytosis and lysosomal degradation is an attractive means to inhibit tumor growth. 
Polyvalent antibodies have been developed to stimulate EGFR and other ErbB endocytosis 
by crosslinking the receptors together [156, 160]. One good example is trastuzumab 
(Herceptin). Trastuzumab is a humanized recombinant mAb that binds to the extracellular 
domain of ErbB2 protein [161, 162]. Currently, it is the only ErbB2-targetted therapy 
approved by FDA for metastatic breast cancer treatment [163]. Although several recent 
studies suggest that Trastuzumab does not induce the endocytosis of ErbB2 to a significant 
degree [154, 156, 157], the dominating opinion has been that Trastuzumab causes endocytic 
downregulation of ErbB2 [2, 164-166]. 
Cetuximab is an antibody targeting EGFR that is currently used in treatment of colorectal 
cancer and head and neck cancer [167]. Several studies have shown that Cetuximab induces 
the internalization of EGFR [109, 168]. Cetuximab-induced EGFR internalization is 
independent of receptor tyrosine kinase activity, and it is both slower and less efficient in 
terms of receptor downregulation than ligand-induced endocytosis [109]. At present, the 
knowledge of mechanisms underlying antibody-mediated endocytic downregulation is 
relatively sparse. A useful observation is that extensive antibody-based crosslinking of ErbB 
receptors is far more efficient at inducing ErbB endocytic downregulation than single 
antibodies are [156, 160]. Crosslinking can either be done using antibodies that form 
multivalent aggregates via secondary antibodies or gold particles (Hommelgaard2004}, or 
by a more clinically relevant approach using combinations of monoclonal antibodies against 
distinct epitopes in an ErbB receptor [160]. Thus, whereas the administration of 
Trastuzumab alone did not induce significant ErbB2 endocytosis, the combination of 
Trastuzumab with another monoclonal antibody to ErbB2 was very efficient at 
downregulating ErbB2. In addition, the combination of two antibodies was much more 
efficient at inhibiting tumor growth in a mouse model compared to Trastuzumab 
administered alone [160, 166]. 
Although the endocytic downregulation of EGFR has been mostly attributed to clathrin-
dependent endocytosis [18], other endocytic pathways have also been proposed during 
recent years, especially following stimulation with high concentrations of EGF [136]. The 
concentration of EGF varies greatly throughout the human body. The EGF concentration in 
most tissue fluid is about 1–2 ng/ml, but it is much higher, up to 100 ng/ml or more, in 
tubular duct lumens of kidney, salivary glands, and the mammary gland [87, 169]. 
Normally, EGFR is not reached by the high luminal concentrations of EGF in these systems, 
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since the receptor is present at the basolateral site of the epithelial cells. However, during 
wound healing or malignant transformation, the tight junctions disappear and allow the 
high concentrations of EGF to access the receptor [170]. Very high EGF concentration can 
also be found in solid tumors [171]. It was reported that at high concentrations of EGF (20 
ng/ml) the receptor became ubiquitinated and was to a high degree internalized by caveolae 
[136]. Incubation of epithelial cells with 30 ng/ml of EGF for 5–20 min resulted in an eight to 
tenfold increase in the number of plasma membrane caveolae due to EGF-induced tyrosine 
phosphorylation of caveolin-1 [172]. Moreover, live cell imaging revealed increased 
dynamics of green fluorescent protein (GFP)-tagged caveolin upon stimulation of cells with 
30 ng/ml EGF. Thus, some studies suggest a role of caveolae in EGFR endocytosis. More 
interesting, it was further revealed by Sigismund et al that EGFRs internalized via CME are 
not targeted for degradation, but instead are recycled to the cell surface. By contrast, 
clathrin-independent internalization preferentially commits the receptor to degradation 
[173]. A prior study has shown that TGFβ receptor is internalized by two distinct endocytic 
pathways, clathrin-mediated endocytosis leading to TGFβ receptor signaling and lipid-raft-
mediated endocytosis leading to the degradation of TGFβ receptor [174]. 
4.2. Signalling endosomes 
The concept of EGFR signalling from endosomes or "signalling endosomes" has been 
gradually developed. Early evidence to support signalling from endosomes was reported in 
middle to late 1980s. These researches showed that internalized EGFR is 
autophosphorylated and catalytically active [175-177]. Various signaling molecules that 
regulate Ras activity, including Grb2, SHC, Sos and GAP, are co-internalized with EGFR 
into endosomes and remain associated with the receptor in endosomes [20, 178-181]. 
Afterwards, more results confirmed the interaction between EGFR and various signaling 
proteins in endosomes [182-186].  
The major evidence supporting endosomal EGFR signalling came from endocytosis 
inhibition experiments. Since the mid 1990s, researchers have developed many ways to 
inhibit EGFR endocytosis and then examine the effects on cell signalling. These experiments 
have yielded mixed results regarding what signalling pathways activated by endosomal 
EGFR and the physiological relevance of EGFR signaling from endosomes. The inhibition of 
EGFR endocytosis by a dominant-negative mutant dynamin enhances the activation of PLC-
γ1 and cell proliferation, but decreases ERK activation [187]. In a study of EGFR 
transactivation by G-protein coupled receptors, it was found that the inhibition of EGFR 
endocytosis by either mutant dynamin or β-arrestin abolished ERK activation [188, 189]. The 
inhibition of EGFR endocytosis by phospholipase D also blocks EGF stimulated-ERK 
activation [125]. However, none of these researches provided a mechanism to explain why 
activated EGFR at the plasma membrane is unable to activate ERK. On the other hand, other 
research showed that the inhibition of EGFR internalization enhances ERK activation [190, 
191]. EGFR efficiently activates mitogen-activated protein kinase in HeLa cells and Hep2 
cells, which is conditionally defective in clathrin-dependent endocytosis by overexpressing 
dominant negative dynamin [191]. Sprouty2 attenuates EGFR ubiquitination and 
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endocytosis, and consequently enhances Ras/ERK signalling [190]. Initially, in the few cases 
where biological end points were measured, inhibition of endocytosis did not result in the 
attenuation of biological effects [187, 192]. These results argue against a physiological 
relevance of endosome-originated signals [193].  
The controversy over endosomal signaling and its physiological relevance is in part due to 
the limitation of current approaches. For example, while it has made significant contribution 
and remains a powerful tool to study endosomal signaling, this endocytosis-inhibition 
approach has its limitations. While the inhibition of EGFR endocytosis eliminates endosomal 
signaling, the retention of EGFR at the cell surface also enhances signaling from the plasma 
membrane. Thus, it is difficult to determine whether the observed effects are due to the lack 
of endosomal signaling or due to prolonged plasma membrane signaling. Blocking EGFR 
endocytosis by mutant dynamin or β-arrestin affects all endocytic events mediated by these 
factors. Thus, it is difficult to determine whether the observed effects are due to the 
inhibition of EGFR endosomal signaling or due to a broad inhibition of endocytosis. 
Moreover, this approach is not suitable for studying the dynamics of endosomal signaling. 
None of these approaches offered mean to get activated receptors inside a cell without initial 
activation at the cell surface [194] 
In the early 2000s, a novel system was established to allow the specific activation of 
endosome-associated EGFR without the initial activation at the plasma membrane and 
without disrupting the overall endocytosis pathway. To specifically activate endosomal 
EGFR, cells were treated with EGF in the presence of AG1478, a specific EGFR tyrosine 
kinase inhibitor, and monensin that blocks the recycling of EGFR. This treatment led to the 
internalization of inactive EGF-EGFR complex into endosomes. The endosome-associated 
EGFR was then activated by removing AG1478 and monensin. No surface EGFR 
phosphorylation was detected [103, 104]. The specific activation of endosome-associated 
EGFR was also achieved without using monensin[103, 104]. In this system EGFR follows the 
same endocytic pathway as the control: EGF receptor is first internalized into Rab5-positive 
endosomes and eventually traffics to lysosomes for degradation. The only difference is that 
the EGF receptor is not activated during its internalization from the plasma membrane to 
endosomes and stops at endosomes until being activated. Thus, this system not only allows 
the generation of specific endosomal signaling of EGFR, but also under a condition very 
similar to the endosomal signaling of EGFR following its activation at the plasma 
membrane. By using this system, it was shown that 1) endosomes can serve as a nucleation 
site for the formation of signaling complexes, 2) endosomal EGFR signaling is sufficient to 
activate the major signaling pathways leading to cell proliferation and survival, and 3) 
endosomal EGFR signaling is sufficient to suppress apoptosis induced by serum-withdrawal 
[103] and to stimulate cell proliferation [195].  
In most cases, the endosomal EGFR signaling is the continuation of EGFR signaling at the 
plasma membrane, serving to maintain EGFR signaling and provide spatial-temporal 
regulation of EGFR signaling. However, in some cases, specific and novel signaling may be 
initiated only from endosomes as these signaling events require factors to be brought 
together by endocytosis. While specific signaling complexes can be assembled through their 
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recruitment to the early endosomal resident protein RAB5, there are no convincing 
examples that specific and novel signaling is initiated from endosomes in the context of 
EGFR signaling. However, it is well illustrated in TGFβ signaling that specific and novel 
signaling may be initiated only from endosomes. TGFβ receptors (TGFβR) become 
phosphorylated at Ser residues and are internalized by endocytosis following ligand 
binding. Once localized into endosomes, TGFβR can bind to SMAD anchor for receptor 
activation (SARA). The protein complex induced phosphorylation of the transcription 
factors SMAD1 or SMAD2 by their Ser/Thr kinase receptors. Upon phosphorylation, SMADs 
are released into the cytoplasm, bind to a cofactor (SMAD4), enter the nucleus, and promote 
gene transcription [137, 174].  
Together, it is clear that EGFR signals from both the plasma membrane and the endosomes, 
and that the signals from both locations are able to activate major signaling pathways, 
stimulate cell proliferation, and promote cell survival. However, following EGF stimulation, 
activated EGF receptors only stay at the plasma membrane briefly (5-10 min), but stay in the 
endosome much longer (1 h) (Fig. 5) [88]. This argues for a more physiologically important 
role for endosomal signaling. The plasma membrane EGFR signaling are usually 
exaggerated by studies with the inhibition EGFR endocytosis, as activated EGFR that stay at 
the plasma membrane are artificially over extended. 
 
Figure 5. A model to describe the EGFR signaling along its endocytic route. Following its activation at 
the plasma membrane EGFR continues to signal along its endocytic route till its degradation in 
lysosome. EGFR signaling from both the plasma membrane and the intracellular endocytic 
compartment regulates major signaling pathways leading to cell proliferation and survival. The 
Activated EGFR may stay 1-5 minutes at the plasma membrane and 1 - 1.5 h along the endocytic 
compartments. PM: plasma membrane. CP: coated pit. CV: coated vesicle.  
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5. Remaining questions, perspectives and future research 
In spite of intensive research and significant progress, many important issues remain 
unsolved regarding EGFR endocytosis and its regulation of cell signaling. One issue is 
clathrin-mediated endocytosis vs non-clathrin-mediated endocytosis. Significant evidence 
supportting the presence of non-clathrin mediated endocytosis and EGFR also internalized 
through non-clathrin mediated endocytic pathways. However, the mechanisms dictating 
which endocytic pathways EGFR follows under various conditions are far from clear and 
the functions of these different endocytic pathways are not clear either. While a few recent 
researchers showed that EGFR undergoes non-clathrin mediated endocytosis at high EGF 
concentrations and leads to EGFR degradation [137], the extensive data that support the role 
of chathrin-mediate endocytosis in EGFR internalization and degradation in lysosomes in 
the past several decades are mostly obtained at high EGF concentrations. A recent study 
showed that during cell mitosis, EGFR follows non-clathrin mediated endocytic pathway 
under both low and high EGF concentrations [107], which suggest that EGF concentration is, 
at least, not the only factor dictating the entry of EGFR into different endocytic pathways. It 
is also difficult to explain why cells choose the much slower non-clathrin mediated 
endocytosis to degrade EGFR, because it provides the heavily phosphorylated EGFR too 
much time to signal before degradation.  
Another issue is the role of EGFR kinase activity in EGFR endocytosis. Both of the opposing 
claims that EGF-induced EGFR endocytosis is dependent on EGFR kinase activity and that it 
is independent of EGFR kinase activity are supported by many data. It is difficult to 
reconcile the differences in the literature. However, a recent piece of research may shed 
some light. It was recently reported that EGF-induced EGFR endocytosis is independent of 
EGFR kinase activity during interphase, but is dependent on EGFR kinase activity during 
mitosis [107]. During mitosis, EGF-induced EGFR endocytosis is slower and independent of 
clathrin [107]. As previous research never distinguished the cells at interphase from cells at 
mitosis and at any given time there is a portion of cells at mitosis, the reported results are 
always a combination of kinase-independent and kinase-dependent endocytosis. Depending 
on the cell type and experimental conditions, the data may vary significantly. Moreover, 
EGFR may also undergo both kinase-dependent and kinase independent endocytosis during 
interphase depending on the cell type and experimental conditions. It has been shown that 
antibody-induced EGFR endocytosis is independent of EGFR kinase activity [109]. Future 
research is needed to elucidate the molecular mechanisms underlying kinase-independent 
and kinase-dependent endocytic pathways.  
Last, but not least, the function and significance of EGFR signaling from endosome vs EGFR 
signaling from the plasma membrane provides room for further research. It is clear that 
EGFR signals from both the plasma membrane and the endosomes, and that the signals 
from both locations are able to activate major signaling pathways, stimulate cell 
proliferation, and promote cell survival. However, the extent of the difference between these 
two signals is unclear. So far, the results have come from either the comparison between 
endosomal signaling and standard EGFR signaling, or the comparison between plasma 
membrane signaling and standard EGFR signaling. A direct comparison between 
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endosomal EGFR signaling and the plasma membrane EGFR signaling is needed to define 
the functional difference and their physiological significance of these two signals. The 
spatio-temporal dynamics of EGFR signaling in controlling cell function has become a new 
focus of current research. EGFR signaling along the endocytic route from the plasma 
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